吉西他滨和多西他赛联合顺铂治疗晚期非小细胞肺癌的近期疗效及安全性分析

Analysis of the Recent Curative Effect and Safety of Gemcitabine plus Cisplatin versus Docetaxel plus Cisplatin in Treatment of Advanced Non-Small Cell Lung Caner

目的比较吉西他滨+顺铂和多西他赛+顺铂治疗晚期非小细胞肺癌(NSCLC)的临床疗效及安全性。方法选取淮安市淮阴医院收治的晚期NSCLC患者共85例为研究对象,分为DP组(多西他赛+顺铂组联合应用,42例)与GP组(吉西他滨+顺铂联合应用,43例)。比较两组患者的近期疗效、治疗期间药物不良反应发生和生存转归情况。结果GP组总有效率(ORR)为44.2%,DP组ORR为45.2%,两组比较差异无统计学意义(P>0.05)。GP组血小板减少、乏力发生率显著高于DP组,体液潴留和腹泻发生率显著低于DP组,差异均有统计学意义(均P<0.05),但多数患者经对症治疗后恢复正常,不影响继续化疗。结论吉西他滨或多西他赛分别联合顺铂作为一线药物治疗晚期NSCLC的疗效相当,患者生存获益相当,且不良反应均可耐受。

Objective To evaluate the clinical efficacy and safety of gemcitabine plus cisplatin versus docetaxel plus cisplatin in advanced non-small cell lung cancer.Methods a total of 85 patients with advanced NSCLC treated in Huai＇an Huaiyin Hospital were divided into DP group（docetaxel ＋ cisplatin group combined with 42 cases） and GP group（gemcitabine ＋ cisplatin combined application, 43 cases）.The short-term efficacy,adverse drug reactions and survival outcomes were compared between the two groups.Results The overall response rates of GP group and DP group were 44.2%、45.2%,respectively.And no significant difference was found between the two groups（P〉0.05）.But the incidence of thrombocytopenia and weakness in GP group was significantly higher than those in DP group（P〈0.05）.Moreover,the incidence of Fluid retention and diarrhea was totally opposite（P〈0.05）.After the symptomatic treatment, patients would be back to normal and resumed chemotherapy.Conclusion GP regimen and DP regimen were equivalent in the treatment of advanced stage NSCLC.Both have good therapeutic effects and tolerated toxic reactions.